GS-US-563-6041: A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV04/06/2023 - 12/31/2027 (PI)
Gilead Sciences
TH-IBA-CTR-1003 PROMISE-US10/27/2022 - 10/27/2025 (PI)
THERATECHNOLOGIES U.S., INC.
Gamma delta T cells promote inflammation in aviremic HIV infection and normal aging08/15/2020 - 05/31/2025 (PI)
Trustees of Boston University, BUMC National Institute o5R01AG065050-03
Launching a geriatrics and HIV-ID integrated clinic to improve care for people aging with HIV: The HIVE program08/01/2022 - 07/31/2024 (PI)
Health Resources and Services Administration/DHHS
Solar GSK213500: A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administer01/25/2021 - 01/24/2024 (PI)
GlaxoSmithKline
Is Integrase Inhibitor Emergent Weight Gain associated with increased Cardiometabolic Risk? A Nationwide Cohort Analysis01/24/2022 - 01/23/2024 (PI)
Gilead Sciences
Real-world Clinical Insights and Inflammatory Mechanisms of Integrase Strand Transfer Inhibitor Associated Excessive Weight Gain07/01/2021 - 12/30/2023 (PI)
The Miriam Hospital National Institute o